Potential application of mesenchymal stem cells in acute lung injury

University of California, Anesthesiology, 505 Parnassus Avenue, Box 0648, San Francisco, CA 94143-0648, USA.
Expert opinion on biological therapy (Impact Factor: 3.65). 09/2009; 9(10):1259-70. DOI: 10.1517/14712590903213651
Source: PubMed

ABSTRACT Despite extensive research into the pathogenesis of acute lung injury and the acute respiratory distress syndrome (ALI/ARDS), mortality remains high at approximately 40%. Current treatment is primarily supportive, with lung-protective ventilation and a fluid conservative strategy. Pharmacologic therapies that reduce the severity of lung injury in experimental studies have not yet been translated into effective clinical treatment options. Therefore, innovative therapies are needed. Recent studies have suggested that bone-marrow-derived multipotent mesenchymal stem cells (MSC) may have therapeutic applications in multiple clinical disorders including myocardial infarction, diabetes, sepsis, hepatic and acute renal failure. Recently, MSC have been studied in several in vivo models of lung disease. This review focuses on first describing the existing experimental literature that has tested the use of MSC in models of ALI/ARDS, and then the potential mechanisms underlying their therapeutic use with an emphasis on secreted paracrine soluble factors. The review concludes with a discussion of future research directions required for potential clinical trials.


Available from: Naveen Gupta, Jan 29, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stem cells (MSCs) are currently being tested in clinical trials for the treatment of various diseases owing to the ease of generating and expanding these cells, the ability to differentiate them into various specialized mesenchymal tissue types and their immunosuppressive properties. However, their immunomodulatory potential remains controversial. This review describes the constitutive and regulated expression of molecules of the major histocompatibility complex (MHC) class I antigen processing machinery (APM), co-stimulatory B7 molecules and HLA-G. Furthermore, this review focuses on the secretion of factors, such as cytokines, in mesenchymal stem cells, their functional role in mounting and controlling immune responses mediated by different immune cell subpopulations, their medical significance, and the obstacles that limit their clinical application.
    Trends in Molecular Medicine 11/2011; 18(2):128-34. DOI:10.1016/j.molmed.2011.10.004 · 10.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stem cells (MSCs) have potent stabilising effects on vascular endothelium injury, inhibiting endothelial permeability in lung injury via paracrine hepatocyte growth factor (HGF). Recently, it has been indicated that MSCs secrete more factors by MSC-endothelial cell (MSC-EC) interactions. We hypothesised that MSC-EC interactions restore endothelial permeability induced by lipopolysaccharide (LPS) via paracrine HGF. We investigated the endothelial permeability induced by LPS under two co-culture conditions. Human pulmonary microvascular endothelial cells (HPMECs) were added into the upper chambers of cell-culture inserts, while two different co-culture conditions were used in the lower side of the transwells, as follows: 1) MSC-EC interaction group: MSCs and HPMECs contact co-culture; 2) MSC group: MSCs only. The endothelial paracellular and transcellular permeability in the upper side of transwells were detected. Then, the concentration of HGF was measured in the culture medium using an Enzyme Linked Immunosorbent Assay (ELISA) kit, followed by neutralisation of HGF with anti-HGF antibody in the co-culture medium. In addition, Adherens junction and cytoskeleton proteins expression were measured by Western blot and immunofluorescence. HPMECs proliferation was analyzed by Bromodeoxyuridine incorporation assay. The paracellular permeability significantly increased after LPS stimulation in a dose-dependent and time-dependent manner. Meanwhile, MSC-EC interaction more significantly decreased endothelial paracellular and transcellular permeability induced by LPS. Moreover, HGF levels in the MSC-EC interaction group were much higher than those of the MSC group. However, neutralising HGF with anti-HGF antibody inhibited the role of MSC-EC interaction in improving endothelial permeability. Compared to the MSC group, MSC-EC interaction increased VE-cadherin and occludin protein expression, reduced caveolin-1 protein expression in HPMECs and restored remodelling of F-actin and junctional localisation of vascular endothelial cadherin (VE)-cadherin. Furthermore proliferation ratio in MSC-EC interaction group was higher than that of MSC group. However, the effects of MSCs was significantly blocked by anti-HGF antibody. These data suggested that MSC-EC interaction decreased endothelial permeability induced by LPS, which was mainly attributed to HGF secreted by MSCs. The main mechanisms by which HGF restored the integrity of endothelial monolayers was remodelling of endothelial intercellular junctions, decreasing caveolin-1 protein expression and inducing proliferation in HPMECs.
    Stem Cell Research & Therapy 03/2015; 6(1):44. DOI:10.1186/s13287-015-0025-1 · 4.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent evidence suggests that loss of endothelial barrier function and resulting microvascular leak play important mechanistic roles in the pathogenesis of infection-related end-organ dysfunction and failure. Several distinct therapeutic strategies, designed to prevent or limit infection-related microvascular endothelial activation and permeability, thereby mitigating end-organ injury/dysfunction, have recently been investigated in pre-clinical models. In this review, these potential therapeutic strategies, namely, VEGFR2/Src antagonists, sphingosine-1-phosphate agonists, fibrinopeptide Bβ 15-42, slit2N, secinH3, angiopoietin-1/tie-2 agonists, angiopoietin-2 antagonists, statins, atrial natriuretic peptide, and mesenchymal stromal (stem) cells, are discussed in terms of their translational potential for the management of clinical infectious diseases.
    Virulence 07/2013; 4(6). DOI:10.4161/viru.25740 · 3.32 Impact Factor